Therefore, in this study, we aimed to identify patients within our B-ALL cohort with altered PAX5 using a comprehensive analysis approach, characterize the types of genetic changes, determine their somatic or germline origin, and analyze the clinical outcomes associated with these alterations, ultimately aiming to improve patient outcomes and provide a better understanding of the role of PAX5 in leukemogenesis. The gene discussed is PAX5; the disease is acute lymphoblastic leukemia.